SPPAM
AGIO icon

Summit Partners Public Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Summit Partners Public Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-101,730
Closed -$4.52M – 150
2024
Q3 		$4.52M Buy
+101,730
New +$4.62M 0.14% 95

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Summit Partners Public Asset Management's AGIO Position: Q4 2024 in Review

Summit Partners Public Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2024, closing a stake of 101,730 shares — an estimated $4.52M sold.

Summit Partners Public Asset Management first reported a position in AGIO in Q3 2024 and held it in 1 quarter. The position peaked at $4.52M in Q3 2024. 225 funds tracked by Wall St. Rank hold AGIO as of Q4 2024.

  • Summit Partners Public Asset Management reported no remaining Agios Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 101,730 Agios Pharmaceuticals shares in Q4 2024, an estimated $4.52M.
  • Summit Partners Public Asset Management first reported a position in Agios Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Summit Partners Public Asset Management's Agios Pharmaceuticals position peaked at $4.52M in Q3 2024.
  • 225 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2024.

Based on Summit Partners Public Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.